-
Corbus Pharmaceuticals NASDAQ:CRBP Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company's lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to immunosuppressive medications in the treatment of chronic inflammatory and fibrotic diseases. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform.
Location: 500 River Ridge Drive, Massachusetts, 02062, US | Website: www.corbuspharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
27.91M
Cash
159.4M
Avg Qtr Burn
-9.215M
Short % of Float
29.52%
Insider Ownership
0.75%
Institutional Own.
-
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CRB-601 (anti-αvβ8) Details Solid tumor/s | Phase 1 Data readout | |
CRB-701 (Nectin-4 ADC) Details Solid tumor/s, Urothelial cancer, Cancer | Phase 1 Data readout | |
CRB-913 Details Obesity | Phase 1 Initiation | |
Lenabasum Details Genetic disorder, Chronic inflammatory disorder, Rare genetic disease, Inflammatory disease | Failed Discontinued | |
Lenabasum (JBT-101) Details Autoimmune disease | Failed Discontinued | |
Lenabasum Details Cystic fibrosis | Failed Discontinued | |
Lenabasum Details Systemic sclerosis | Failed Discontinued |